Ligand-modified cell membrane enables the targeted delivery of drug nanocrystals to glioma

Summary

This preclinical drug-delivery study combines high-loading drug nanocrystals with a ligand-engineered red-blood-cell membrane to improve chemotherapy targeting. Targeting peptides were inserted into the membrane through avidin–biotin interactions, after which the modified membrane was wrapped around drug nanocrystals. The baseline membrane-coated formulation offered high drug content, long-term stability, biocompatibility, and prolonged retention. Adding the cyclic RGD peptide c(RGDyK) created a tumor-targeted version intended to recognize relevant tumor-associated integrins. In mice, these targeted nanocrystals accumulated in tumors more strongly and produced better therapeutic effects in both a subcutaneous tumor model and an orthotopic glioma model. The principal finding is that the membrane coating and peptide modification can be layered onto a carrier composed largely of drug itself, combining efficient loading and circulation behavior with active tumor recognition. Its significance is a modular approach that may avoid the low drug fraction of some conventional nanoparticles and could be adapted to other drug–cancer combinations. The abstract does not identify the drug, quantify accumulation or survival, describe blood–brain-barrier transport, compare toxicity, or establish how readily avidin–biotin modification can be translated.